
Can-Fite BioPharma Ltd. CANF
$ 4.86
2.32%
Annual report 2024
added 02-21-2026
Can-Fite BioPharma Ltd. Depreciation & Amortization 2011-2026 | CANF
Annual Depreciation & Amortization Can-Fite BioPharma Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 14 K | 14 K | 12 K | 14 K | 14 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14 K | 12 K | 13.6 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Xeris Pharmaceuticals
XERS
|
1.31 M | $ 6.03 | -1.55 % | $ 885 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
UroGen Pharma Ltd.
URGN
|
307 K | $ 19.2 | -11.52 % | $ 554 M | ||
|
uniQure N.V.
QURE
|
14.8 M | $ 10.89 | -30.36 % | $ 530 M | ||
|
GT Biopharma
GTBP
|
4 K | $ 0.47 | -2.41 % | $ 892 K | ||
|
AbCellera Biologics
ABCL
|
18.4 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
13.6 M | $ 3.36 | 0.86 % | $ 1.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
5.2 M | $ 29.16 | -3.54 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Alector
ALEC
|
5.72 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
238 K | $ 4.21 | -2.32 % | $ 299 M | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
3.02 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
AbbVie
ABBV
|
762 M | $ 233.57 | 0.64 % | $ 413 B | ||
|
Blueprint Medicines Corporation
BPMC
|
16.3 M | - | - | $ 8.14 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
AIM ImmunoTech
AIM
|
38 K | $ 0.8 | -11.6 % | $ 38.5 M | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.83 | 5.37 % | $ 4.53 M | ||
|
Apellis Pharmaceuticals
APLS
|
1.56 M | $ 20.67 | -1.38 % | $ 2.61 B |